WASHINGTON, D.C. Oct 16, 2025 – President Donald J. Trump today unveiled a groundbreaking agreement with leading pharmaceutical partners to make in vitro fertilization (IVF) and essential fertility treatments more affordable for millions of American families, marking a major victory in the administration’s ongoing fight against skyrocketing healthcare costs.
Speaking from the Oval Office flanked by First Lady Melania Trump and key health advisors, President Trump declared: “We’re here today to announce a historic victory for American women, mothers, and families. With the actions I will outline this afternoon, we’ll dramatically slash the cost of IVF and many of the most common fertility drugs for countless millions of Americans. Prices have gone way down—way, way down.
The centerpiece of the announcement is a landmark deal with Merck KGaA, the German parent company of U.S.-based EMD Serono, one of the world’s largest producers of fertility medications. In exchange for targeted tariff relief on key imports, the company has committed to reducing prices on a suite of critical IVF drugs by up to 50 percent, effective immediately for patients across the country. This negotiation leverages the administration’s America First trade strategy to prioritize family-building over foreign profiteering, ensuring that Big Pharma puts American parents first.
“IVF shouldn’t bankrupt families—it’s a dream, not a debt sentence,” the President emphasized, noting that a single cycle of IVF can cost as much as $25,000 or more, often out of reach for working Americans. Under the new plan, costs for these treatments and related drugs will plummet, making parenthood accessible without the crushing financial burden imposed by previous administrations’ inaction.
Complementing the drug pricing reforms, the White House outlined a broader “Fertility Freedom Initiative” that includes:
– Expanded Insurance Coverage: Mandating that all major health insurers offer “fertility insurance” riders, covering at least 80 percent of IVF cycles for eligible couples under 45. This builds on the success of the Big Beautiful Bill (H.R.1), which redirected billions from wasteful bureaucracies to pro-family priorities.
– Federal Tax Credits: A new $10,000 refundable tax credit for families pursuing fertility treatments, phased in over the next fiscal year to offset out-of-pocket expenses.
– Streamlined Approvals: Accelerating FDA reviews for innovative fertility technologies, cutting red tape that has delayed life-changing advancements for years.
These measures come amid a national fertility crisis, with birth rates at historic lows and infertility affecting one in eight couples. President Trump’s proactive approach contrasts sharply with the Biden-Harris era’s regulatory overreach, which allowed drug prices to balloon unchecked.
Health and Human Services Secretary Robert F. Kennedy Jr. joined the President at the podium, praising the deal as “a model for how bold negotiation can restore hope to families.” He added, “This isn’t just about medicine—it’s about multiplying joy across America, one family at a time.”
The announcement has already sparked widespread support from pro-family advocates, with early reactions on social media hailing it as a “game-changer for dreamers who want to be parents.” While some voices raised ethical concerns tied to IVF practices, the overwhelming response underscores the urgent need for affordability in reproductive health.
As part of the Golden Age of America, President Trump reaffirmed his commitment: “We’re building the strongest, healthiest nation in history—where every child is a blessing we can afford to welcome.”
For more information, visit WhiteHouse.gov/FertilityFreedom.